Evidence map›Paper›PMID 34417567›Full record

ArticleThe Journal of antibiotics2021

Identification of pulvomycin as an inhibitor of the futalosine pathway.

Yasushi Ogasawara, Shuhei Umetsu, Yuki Inahashi, Kenichi Nonaka, Tohru Dairi

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. The Structural and Molecular Mechanisms ofMolecules (Basel, Switzerland) · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yasushi OgasawaraGraduate School of Engineering, Hokkaido University, Sapporo, Hokkaido, Japan. yogasawa@eng.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-3144-3985
Shuhei UmetsuGraduate School of Chemical Sciences and Engineering, Hokkaido University, Sapporo, Hokkaido, Japan.
Yuki InahashiŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.
Kenichi NonakaŌmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan.
Tohru DairiGraduate School of Engineering, Hokkaido University, Sapporo, Hokkaido, Japan. dairi@eng.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-3406-7970
Hokkaido University · JPKitasato Institute Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Menaquinone is an essential cofactor in the electron-transfer pathway for bacteria. Menaquinone is biosynthesized from chorismate using either the well-known canonical pathway established by pioneering studies in model microorganisms or the futalosine pathway, which we discovered in Streptomyces. Because Helicobacter pylori, which causes stomach cancer, uses the futalosine pathway and most beneficial intestinal bacteria including lactobacilli use the canonical pathway, the futalosine pathway will be a great target to develop antibiotics specific for H. pylori. Here, we searched for such compounds from metabolites produced by actinomycetes and identified pulvomycin from culture broth of Streptomyces sp. K18-0194 as a specific inhibitor of the futalosine pathway.

Indexed as

ActinobacteriaAminoglycosidesAnti-Bacterial AgentsCulture MediaHelicobacter pyloriNucleosidesSignal TransductionStreptomycesAminoglycosidesAnti-Bacterial AgentsCulture MediafutalosineNucleosidespulvomycin

Identifiers

PMID34417567
OpenAlexW3194905210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.